Antibiotic News and Research

RSS

Antibiotics are drugs used to treat infections caused by bacteria and other microorganisms.

Patients and surgeons drive demand for elective orthopedic procedures despite economic slowdown

According to Millennium Research Group (MRG), the global authority on medical technology market intelligence, patients and surgeons are driving demand for elective orthopedic procedures.

7 Oct 2009

Rapid viral testing might benefit health systems

Rapid viral diagnosis tests for respiratory diseases in children who arrive in emergency departments have the potential to reduce pressures on health systems by enabling doctors to reach a quicker diagnosis, according to Cochrane Researchers. However, they say larger trials are needed to confirm this finding.

7 Oct 2009

Research on malarial drugs for travelers

A new review of existing research finds that a combination drug and the common antibiotic doxycycline allow travelers to fend off malaria with the fewest side effects in areas where the parasite is resistant to a widely accepted preventive treatment.

7 Oct 2009

Gen-Probe to acquire Prodesse for $60 million in cash

Gen-Probe Incorporated announced today that it has signed a definitive agreement to acquire Prodesse, Inc., a privately held leader in molecular testing for influenza and other infectious diseases, for approximately $60 million in cash. Gen-Probe's purchase price could increase to up to $85 million if Prodesse achieves certain financial and regulatory milestones in 2010 and 2011.

7 Oct 2009

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Pharma Major, Lupin Ltd today announced that it has granted Salix Pharmaceuticals, Ltd. the exclusive rights for the United States to its bioadhesive drug delivery technology for use with Rifaximin.

6 Oct 2009

Antibiotic minocycline may be used for treatment of strokes: Study

The antibiotic minocycline may revolutionize the treatment of strokes. A new study, published in the open access journal BMC Neuroscience, describes the safety and therapeutic efficacy of the drug in animal models.

6 Oct 2009

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Salix Pharmaceuticals, Ltd. today announced that as of September 30, 2009 Lupin Ltd. granted Salix the exclusive right in the United States to its bioadhesive drug delivery technology for use with rifaximin. Salix and Lupin have entered into a development, commercialization and license agreement under which the two companies will collaborate in the development and commercialization of a product incorporating rifaximin and utilizing Lupin’s proprietary technology.

5 Oct 2009

Prompt diagnosis and treatment for otitis media benefits organ transplant recipients

Organ transplant recipients benefit significantly when they are monitored and receive prompt diagnosis and treatment for otitis media, a common inner ear infection.

5 Oct 2009

Report on the worldwide market for anti-infectives

Drug resistance is a key public health problem and also a problem for makers of branded antibacterial products, according to the findings of a new report. Traditional antibiotics: quinolones, cephalosporins, and penicillins, have seen their market share erode due to loss of effectiveness, while at the same time they are facing heavy generic competition.

3 Oct 2009

CSPI sues Bayer for false claims on Men's One A Day multivitamins

The Center for Science in the Public Interest has sued the German drug company Bayer for falsely claiming that the selenium in Men's One A Day multivitamins might reduce the risk of prostate cancer. The lawsuit is filed in the Superior Court of California in San Francisco.

3 Oct 2009

Avexa's ATC Phase III study concludes

Avexa Limited today announced that the apricitabine (ATC) Phase III study will be closed and the data will be subsequently unblinded and analyzed. After extensive interaction with the regulatory authorities and potential partners, the decision was made to evaluate the 24 week data with the results due in the first quarter of 2010.

3 Oct 2009

CNN, TIME examine increasing antibiotic resistance

CNN examines a recent report by researchers that warns of increasing antibiotic resistance and appeals for governments to take action to develop new antibiotics to avert a health crisis.

3 Oct 2009

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Astellas Pharma Canada, Inc. announced today that Health Canada has approved VIBATIV(TM) (telavancin) for the treatment of adult patients with complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive bacteria, including Staphylococcus aureus, both methicillin-resistant (MRSA) and methicillin-susceptible (MSSA) strains.

1 Oct 2009

Screening and diagnostic tests contribute to health care value across spectrum of care

Amidst ongoing debate in Congress over reforming the nation's health care system, a new report from the Lewin Group finds that screening and diagnostic laboratory tests are central to achieving some of the most important goals of health care reform.

1 Oct 2009

Study aims to discover effective antibiotics to fight against hard-to-treat microbes

Scientists are reporting discovery of a much sought after crack in the armor of a common microbe that infects the stomachs of one-sixth of the world's population, causing stomach ulcers and other diseases. They identified a group of substances that block a key chemical pathway that the bacteria need for survival.

1 Oct 2009

TheraDoc's patient safety surveillance system helps hospitals manage their H1N1 responses effectively

As the battle against the H1N1 influenza outbreak continues, hospitals are on the front lines, charged with identifying, treating, monitoring, and reporting flu cases—as well as preventing their spread to other patients and hospital personnel. To facilitate this arduous task, a growing number of U.S. hospitals are using a patient safety surveillance system developed by TheraDoc that helps them more effectively coordinate their responses to this serious public health threat.

30 Sep 2009

Non-human primate study results of Restanza released

Advanced Life Sciences Holdings, Inc., today announced positive top-line results from a pivotal, non-human primate study involving its novel, once-a-day, oral antibiotic Restanza(TM) (cethromycin) demonstrating statistical significance at a 90% survival rate against an inhaled lethal dose of plague.

30 Sep 2009

Polymedix commences Phase 1B study of novel anticoagulant reversing agent

PolyMedix, Inc., an emerging biotechnology company developing new therapeutic drug products to treat infectious diseases and acute cardiovascular disorders based on biomimetics, has initiated dosing and commenced a second clinical trial, a Phase 1B pilot proof of concept study, in the U.S. with its anticoagulant reversing agent PMX-60056 under an Investigational New Drug application (IND) filed with the U.S. Food and Drug Administration (FDA).

30 Sep 2009

Automated SafetySurveillor system to detect healthcare-associated infections

The Premier healthcare alliance today announced that Bon Secours St. Francis Medical Center of Midlothian, Va., selected Premier’s SafetySurveillor® Web-based infection tracking and antimicrobial utilization tool. More than 270 hospitals use SafetySurveillor to help prevent healthcare-associated infections (HAIs) and optimize antibiotic use, thereby protecting patients more effectively while safely reducing hospital costs.

30 Sep 2009

Oculus launches Microcyn Skin & Wound HydroGel OTC

Oculus Innovative Sciences, Inc., a biopharmaceutical company that develops, manufactures and markets a family of products based upon the Microcyn Technology platform, which is intended to treat chronic and acute wounds, today launched Microcyn Skin & Wound HydroGel for both the U.S. professional and over-the-counter markets. The Microcyn HydroGel received FDA 510(k) marketing clearance in May of this year.

29 Sep 2009

Antibiotic News and Research

Further Reading

Patients and surgeons drive demand for elective orthopedic procedures despite economic slowdown

Rapid viral testing might benefit health systems

Research on malarial drugs for travelers

Gen-Probe to acquire Prodesse for $60 million in cash

Salix Pharmaceuticals granted rights to use Lupin's bioadhesive drug delivery technology

Antibiotic minocycline may be used for treatment of strokes: Study

Lupin grants Salix exclusive rights to its bioadhesive drug delivery technology for use with rifaximin

Prompt diagnosis and treatment for otitis media benefits organ transplant recipients

Report on the worldwide market for anti-infectives

CSPI sues Bayer for false claims on Men's One A Day multivitamins

Avexa's ATC Phase III study concludes

CNN, TIME examine increasing antibiotic resistance

Health Canada approves VIBATIV for treating complicated skin and skin structure infections

Screening and diagnostic tests contribute to health care value across spectrum of care

Study aims to discover effective antibiotics to fight against hard-to-treat microbes

TheraDoc's patient safety surveillance system helps hospitals manage their H1N1 responses effectively

Non-human primate study results of Restanza released

Polymedix commences Phase 1B study of novel anticoagulant reversing agent

Automated SafetySurveillor system to detect healthcare-associated infections

Oculus launches Microcyn Skin & Wound HydroGel OTC

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News